Evidence map›Paper›PMID 36564561›Full record

ArticleBritish journal of cancer2023

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

Monique K van der Kooij, Arjen Joosse, Karijn P M Suijkerbuijk, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, John B A G Haanen and 9 more

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 2 countries.

Monique K van der KooijDepartment of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.ORCID 0000-0002-9764-5467
Arjen JoosseDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.
Karijn P M SuijkerbuijkDepartment of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Maureen J B AartsDepartment of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands.
Franchette W P J van den BerkmortelDepartment of Medical Oncology, Zuyderland Medical Center, 6130 MB, Sittard-Geleen, The Netherlands.
Christian U BlankDepartment of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.ORCID 0000-0002-7945-5846
Marye J Boers-SonderenDepartment of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, The Netherlands.
Alfonsus J M van den EertweghDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HZ, Amsterdam, The Netherlands.
Jan Willem B de GrootIsala Oncology Center, Isala, 8000 GK, Zwolle, The Netherlands.
John B A G HaanenDepartment of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Geke A P HospersDepartment of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.ORCID 0000-0002-3047-7892
Djura PiersmaDepartment of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands.
Rozemarijn S van RijnDepartment of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands.
Astrid A M van der VeldtDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.ORCID 0000-0003-0446-1907
Gerard VreugdenhilDepartment of Medical Oncology, Maxima Medical Center, de Run 4600, 5500 MB, Veldhoven, The Netherlands.
Hans M WestgeestDepartment of Medical Oncology, Amphia Ziekenhuis, Langendijk 175, 4819 EV, Breda, The Netherlands.ORCID 0000-0002-5735-3638
Michel W J M WoutersDutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands.
Olaf M DekkersDepartment of Clinical Epidemiology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.
Ellen KapiteijnDepartment of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands. h.w.kapiteijn@lumc.nl.
Leiden University Medical Center · NLThe Netherlands Cancer Institute · NLErasmus MC Cancer Institute · NLRadboud University Nijmegen · NLAmphia Ziekenhuis · NLAmsterdam Neuroscience · NLHeidelberg University · DEIsala · NLMaastricht University Medical Centre · NLMedisch Centrum Leeuwarden · NLMedisch Spectrum Twente · NLUniversity Medical Center Groningen · NLZuyderland Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MelanomaProgrammed Cell Death 1 ReceptorCohort StudiesHumansNivolumabNivolumabProgrammed Cell Death 1 Receptor

Identifiers

PMID36564561
PMCPMC9977837
OpenAlexW4312130004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.